Press release
BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis
April 5, 2023Business Services
London, UK, 5 April 2023: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI) announces top-line results from its Phase IIa, …
Phlo acquires Truepill UK in landmark digital pharmacy consolidation
April 4, 2023Business Services
Glasgow, UK. Phlo Technologies UK digital pharmacy leaders, have today announced their acquisition of the UK arm of US-based healthcare …
Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO
April 4, 2023Business Services
Cambridge, UK, 04 April 2023 – Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company dedicated to resolving …
Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration
April 4, 2023Business Services
Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on …
PHARMANOVIA RECEIVES SBTi APPROVAL FOR NET ZERO EMISSION TARGETS
April 4, 2023Business Services
Basildon, UK, 3 April 2023 Pharmanovia, a global pharmaceutical company that revitalises, extends and expands the lifecycle of already established …
Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
April 4, 2023Business Services
New Jersey, USA, and Oxford, UK, 3rd April 2023: Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a …
CrestOptics launches CICERO system to provide all-in-one solution for widefield and spinning disk confocal microscopy
April 3, 2023Business Services
Rome, IT, 03 April, 2023: CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and …
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
April 3, 2023Business Services
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana
Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
April 3, 2023Business Services
Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases …
Redx Confirms Proposed Business Combination with Jounce has Formally Lapsed
April 3, 2023Business Services
Alderley Park, UK, 3 April 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
March 31, 2023Business Services Almirall, Dermatology, dermatology, lebrikizumab
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 31, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Friday, March 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that …
Expansion of Scientific Affairs Group
March 30, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
March 30, 2023Business Services
London, UK, March 30, 2023 – Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating …
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
March 30, 2023Business Services
Netanya, Israel, March 30, 2023 – Trobix Bio, a company utilizing CRISPR, phage, and synthetic biology technologies to develop advanced …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
